Raymond James lowered the firm’s price target on Bausch Health (BHC) to $8 from $9 and keeps a Market Perform rating on the shares. Bausch Health reported a “solid” Q1 overall, with adjusted EBITDA and revenue strength across all businesses except Bausch + Lomb (BLCO) and International, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health price target lowered to $8 from $9 at Raymond James
- Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns
- Bausch Health Earnings Call Highlights Growth and Challenges
- Cautious Outlook on Bausch Health: Sell Rating Amid Strategic Uncertainty and Tariff Concerns
- Bausch Health Reports Q1 2025 Financial Results